PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals

• Auteurs principaux: Ji Young Kim (Auteur), Ji Hye Shin (Auteur), Mi-Jeong Kim (Auteur), Bongkum Choi (Auteur), Yeeun Kang (Auteur), Jimin Choi (Auteur), Seo Hyun Kim (Auteur), Dohee Kwan (Auteur), Duk-Hwan Kim (Auteur), Eunyoung Chun (Auteur), Ki-Young Lee (Auteur)
• Format: Livre
• Publié: BMC, 2024-05-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Abstract Protein tyrosine kinase 2 (PTK2), epidermal growth factor receptor (EGFR), and toll-like receptor (TLRs) are amplified in non-small cell lung cancer (NSCLC). However, the functional and clinical associations between them have not been elucidated yet in NSCLC. By using microarray data of non...